Results 91 to 100 of about 1,722,968 (253)
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
Nature Communications, 2019 The BCL-2 mutation G101V reduces venetoclax affinity and confers drug resistance in patients with chronic lymphocytic leukaemia. Here, the authors present crystal structures and biochemical analyses of venetoclax bound to BCL-2 and the G101V mutant ...
Richard W. Birkinshaw +13 more
doaj +1 more source
Evaluation of genomic aberrations to define treatment response predictors in chronic lymphocytic leukaemia: Genetic predictors of CLL treatment outcomes [PDF]
Chronic lymphocytic leukaemia is a clinically and genetically heterogenous disease. Despite advances in therapeutics, markers to predict response to treatments are lacking, particularly in the setting of chemotherapy resistance. During the course of this
Clifford, Ruth
core +1 more source
Biotechnology and Bioengineering, EarlyView.Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga +2 more
wiley +1 more source
Tackling cancer stemness with nanotechnology in the era of precision medicine
BMEMat, EarlyView.Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo +9 more
wiley +1 more source
Gyriform Susceptibility Rim in Early Progressive Multifocal Leukoencephalopathy
Annals of Neurology, EarlyView.
Thor Linnet, Karan Dixit, Shailee Shah
wiley +1 more source
BMEMat, EarlyView.Nanomedicine‐Driven Strategies for Suppressing Postoperative Tumor Recurrence. This schematic illustrates three pivotal nanomedical strategies that synergistically counteract recurrence by targeting residual disease and the immunosuppressive tumor microenvironment within the surgical cavity.
Lisong Pang +8 more
wiley +1 more source
Clinical Advances in Periodontics, EarlyView.Abstract Background Necrotizing periodontal diseases (NPDs) are uncommon and severe inflammatory conditions characterized by tissue necrosis, painful ulceration, and rapid clinical progression, frequently associated with systemic immunosuppression. Limited data exist regarding their clinical presentation and management in hospital settings.
Osmaria Letthycia Carvalho Leal +8 more
wiley +1 more source
From Prediction to Decision Making: PBPK and QSP as Regulatory‐Grade NAMs
Clinical Pharmacology &Therapeutics, EarlyView.New approach methodologies (NAMs) encompass a diverse and rapidly evolving set of experimental and computational tools designed to generate human‐relevant mechanistic data for use in drug development and regulatory decision making. Experimental NAMs provide insights into drug disposition, pharmacological activity, and disease biology that are difficult
Karen Rowland Yeo, Piet H. van der Graaf
wiley +1 more source
BMJ OpenObjectives Leukaemias and lymphomas are among the most prevalent and significant cancers in Australasia and Oceania. This study aims to examine the burden of leukaemias/lymphomas and its temporal trend in Australasia and Oceania from 2010 to 2019.Design ...
Lan Gao, Peter Lee, Thi Quynh Anh Ho
doaj +1 more source
Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics
Nature Communications, 2019 The definition of regulatory landscape at chronic lymphocytic leukaemia (CLL) risk loci is limited. Here, the authors perform an epigenomic characterisation of 42 known risk loci in CLL and normal B cells at different developmental stages and show active
Helen E. Speedy +17 more
doaj +1 more source